Primary	O
clinical	O
outcome	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
28	B-TimeFrame
-	I-TimeFrame
day	I-TimeFrame
mortality	B-PrimaryOutcome
,	O
no	O
patient	O
died	O
(	O
0	O
%	O
)	O
in	O
the	O
treatment	O
group	O
,	O
while	O
five	O
patients	O
died	O
(	O
12	O
.	O
8	O
%	O
)	O
in	O
the	O
standard	O
group	O
;	O
P	O
=	O
0	O
.	O
027	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Among	O
patients	O
in	O
the	O
treatment	O
arm	O
with	O
bromhexine	O
,	O
two	O
patients	O
were	O
admitted	O
to	O
ICU	O
(	O
5	O
.	O
1	O
%	O
)	O
while	O
in	O
the	O
standard	O
arm	O
,	O
eleven	O
patients	O
(	O
28	O
.	O
2	O
%	O
)	O
were	O
transferred	O
to	O
ICU	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
ICU	B-PrimaryOutcome
admission	I-PrimaryOutcome
between	O
the	O
treatment	O
and	O
the	O
standard	O
group	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

Moreover	O
,	O
among	O
patients	O
in	O
bromhexine	O
arm	O
,	O
one	O
patient	O
received	O
mechanical	O
ventilation	O
(	O
2	O
.	O
6	O
%	O
)	O
,	O
while	O
in	O
the	O
standard	O
arm	O
nine	O
patients	O
(	O
23	O
.	O
1	O
%	O
)	O
were	O
intubated	O
and	O
underwent	O
mechanical	O
ventilation	O
.	O

There	O
was	O
also	O
a	O
highly	O
significant	O
difference	O
in	O
the	O
intubation	B-PrimaryOutcome
and	I-PrimaryOutcome
mechanical	I-PrimaryOutcome
ventilation	I-PrimaryOutcome
between	O
the	O
two	O
groups	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
as	O
shown	O
in	O
Table	O
2	O
.	O

Secondary	O
clinical	O
outcomes	O

There	O
was	O
also	O
a	O
significant	O
difference	O
in	O
the	O
secondary	O
outcome	O
of	O
this	O
study	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Improvement	B-SecondaryOutcome
of	I-SecondaryOutcome
cardinal	I-SecondaryOutcome
respiratory	I-SecondaryOutcome
symptoms	I-SecondaryOutcome
such	I-SecondaryOutcome
as	I-SecondaryOutcome
cough	I-SecondaryOutcome
and	I-SecondaryOutcome
dyspnea	I-SecondaryOutcome
within	B-TimeFrame
two	I-TimeFrame
weeks	I-TimeFrame
among	O
the	O
two	O
groups	O
were	O
assessed	O
:	O

Dyspnea	O
remained	O
in	O
3	O
.	O
4	O
%	O
in	O
the	O
treatment	O
group	O
vs	O
48	O
.	O
3	O
%	O
in	O
the	O
standard	O
group	O
P	O
≤	O
0	O
.	O
001	O
and	O
cough	O
remained	O
in	O
the	O
treatment	O
group	O
6	O
.	O
9	O
%	O
vs	O
40	O
.	O
0	O
%	O
in	O
the	O
standard	O
group	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

Similar	O
results	O
for	O
lassitude	B-SecondaryOutcome
between	O
the	O
two	O
groups	O
were	O
observed	O
(	O
6	O
.	O
9	O
%	O
vs	O
34	O
.	O
5	O
%	O
,	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O

At	O
baseline	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
fever	B-SecondaryOutcome
,	O
headache	B-SecondaryOutcome
,	O
and	O
gastrointestinal	B-SecondaryOutcome
symptoms	I-SecondaryOutcome
between	O
the	O
two	O
groups	O
.	O

The	O
patients	O
in	O
the	O
bromhexine	O
group	O
showed	O
improvement	B-SecondaryOutcome
in	I-SecondaryOutcome
the	I-SecondaryOutcome
level	I-SecondaryOutcome
of	I-SecondaryOutcome
LDH	I-SecondaryOutcome
(	O
363	O
.	O
2	O
±	O
83	O
.	O
6	O
vs	O
.	O
445	O
.	O
3	O
±	O
115	O
.	O
2	O
;	O
P	O
=	O
0	O
.	O
056	O
)	O
,	O
NLR	B-SecondaryOutcome
[	O
1	O
.	O
7	O
(	O
1	O
.	O
0	O
)	O
vs	O
.	O
3	O
.	O
0	O
(	O
6	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
052	O
]	O
and	O
CRP	B-SecondaryOutcome
[	O
0	O
%	O
vs	O
.	O
81	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
]	O
within	B-TimeFrame
two	I-TimeFrame
weeks	I-TimeFrame
compared	O
to	O
the	O
standard	O
group	O
(	O
Table	O
2	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
length	B-SecondaryOutcome
of	I-SecondaryOutcome
stay	I-SecondaryOutcome
in	I-SecondaryOutcome
the	I-SecondaryOutcome
hospital	I-SecondaryOutcome
[	B-TimeFrame
from	I-TimeFrame
randomization	I-TimeFrame
to	I-TimeFrame
discharge	I-TimeFrame
]	I-TimeFrame
between	O
the	O
two	O
groups	O
(	O
treatment	O
7	O
.	O
6	O
±	O
3	O
.	O
5	O
days	O
and	O
standard	O
8	O
.	O
1	O
±	O
5	O
.	O
5	O
days	O
;	O
P	O
=	O
0	O
.	O
587	O
)	O
.	O

